JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Ocular Therapeutix Inc

Slēgts

SektorsVeselības aprūpe

12.61 3.19

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.02

Max

12.64

Galvenie mērījumi

By Trading Economics

Ienākumi

-16M

-64M

Pārdošana

-6.4M

11M

Peļņas marža

-602.342

Darbinieki

274

EBITDA

-20M

-64M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+34.16% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

643M

2B

Iepriekšējā atvēršanas cena

9.42

Iepriekšējā slēgšanas cena

12.61

Ziņu noskaņojums

By Acuity

20%

80%

30 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

Ocular Therapeutix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 11. aug. 17:49 UTC

Galvenie tirgus virzītāji

180 Life Sciences Stock Jumps on $156 Million Notes Sale

2025. g. 11. aug. 17:18 UTC

Galvenie tirgus virzītāji

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

2025. g. 11. aug. 16:25 UTC

Peļņas

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

2025. g. 11. aug. 23:50 UTC

Tirgus saruna

Nikkei May Rise as Yen Weakens -- Market Talk

2025. g. 11. aug. 23:42 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 11. aug. 23:42 UTC

Tirgus saruna

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

2025. g. 11. aug. 23:36 UTC

Tirgus saruna

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2025. g. 11. aug. 23:32 UTC

Tirgus saruna

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

2025. g. 11. aug. 23:02 UTC

Tirgus saruna

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

2025. g. 11. aug. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 11. aug. 20:37 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

2025. g. 11. aug. 20:37 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Bakkt Holdings 2Q Rev $577.9M >BKKT

2025. g. 11. aug. 20:37 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

2025. g. 11. aug. 20:22 UTC

Peļņas

Exodus Movement 2Q Rev $25.8M >EXOD

2025. g. 11. aug. 20:14 UTC

Tirgus saruna

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

2025. g. 11. aug. 19:12 UTC

Tirgus saruna

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

2025. g. 11. aug. 18:56 UTC

Tirgus saruna

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

2025. g. 11. aug. 18:31 UTC

Tirgus saruna

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

2025. g. 11. aug. 17:43 UTC

Tirgus saruna

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

2025. g. 11. aug. 17:28 UTC

Tirgus saruna

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

2025. g. 11. aug. 17:16 UTC

Tirgus saruna

Commodity Longs Fall to 11-Month Low -- Market Talk

2025. g. 11. aug. 16:42 UTC

Iegādes, apvienošanās, pārņemšana

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

2025. g. 11. aug. 16:27 UTC

Iegādes, apvienošanās, pārņemšana

BBVA Says Sabadell Offer Remains in Effect

2025. g. 11. aug. 16:26 UTC

Iegādes, apvienošanās, pārņemšana

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

2025. g. 11. aug. 16:25 UTC

Iegādes, apvienošanās, pārņemšana

Banco de Sabadell Announced TSB Sale on July 1

2025. g. 11. aug. 16:25 UTC

Iegādes, apvienošanās, pārņemšana

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Salīdzinājums

Cenas izmaiņa

Ocular Therapeutix Inc Prognoze

Cenas mērķis

By TipRanks

34.16% augšup

Prognoze 12 mēnešiem

Vidējais 16.85 USD  34.16%

Augstākais 21 USD

Zemākais 12.5 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ocular Therapeutix Inc  — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

11 ratings

10

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

6.97 / 7.62Atbalsts un pretestība

Īstermiņā

Bearish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

30 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.